StockData

Caris Life Sciences vs Natera

CAI and NTRA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CAI and NTRA compare

Natera is the larger company, worth 7.4 times as much as Caris Life Sciences ($41.4B against $5.6B).

Caris Life Sciences grew revenue faster over the last twelve months (61.5% versus 37.8% for Natera).

Caris Life Sciences keeps more of each dollar of sales as profit, with a net margin of 9.2% compared with −7.1% at Natera.

Natera scores higher on the StockData Score (10 against 7 for Caris Life Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCAINTRA
Size and price
Market cap$5.6B$41.4B
Share price$19.94$287.47
Change, 1 year−16.4%40.7%
Change, 5 years–204%
Beta (5Y)2.531.81
Employees1,8466,140
StockData Score
Total score710 (better)
Valuation score00
Growth score13 (better)
Performance score3 (better)2
Health score35 (better)
Dividend score00
Valuation
P/S5.4× (better)15.3×
P/B8.8× (better)22.7×
EV/EBITDA36.5×–
P/FCF195× (better)492×
FCF yield0.51% (better)0.20%
Fair value$10.35$120.81
Margin of safety−92.6% (better)−138%
Growth
Revenue growth (TTM)61.5% (better)37.8%
Revenue growth, 5Y average–42.6%
Profitability
Operating margin13.4% (better)−10.7%
Net margin9.2% (better)−7.1%
FCF margin2.8%3.1% (better)
Return on equity17.2% (better)−12.5%
Return on invested capital26.8% (better)−40.8%
Financial health
Debt / equity0.610.04 (better)
Net debt / EBITDA1.79–
Interest coverage3.3× (better)−75.9×
Current ratio6.71 (better)3.00
Altman Z-score4.7329.36 (better)
Piotroski F-score6 (better)5
Dividends and buybacks
Buyback yield0.56%–
Shareholder yield0.56% (better)0.00%
Ownership
Held by institutions54.5%95.2%
Held by insiders64.1%3.9%
Insider net buying, 12 months−$27.4M (better)−$342M
Superinvestors holding23 (better)
Short interest, % of float11.3%4.4%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.